← All organizations
Highest phase reached
Phase 3
First clinical trial
Jun 1, 2004First marketed drug
Dec 18, 2024First NDA
Dec 18, 2024Last known activity
Dec 18, 2024
Timeline
2000s
- Jun 1, 2004
Mesoblast, Inc.— Founded
2010s
- May 12, 2010
Angioblast Systems— Acquired
2020s
- Dec 18, 2024
bone marrow derived mesenchymal stem cells— NDA Organization
Drugs by trial phase (24 distinct, 39 trials)
Phase 3 (4 own, 2 via acquisition)
Phase 2 (16 own, 0 via acquisition)
Other trials (2 own, 0 via acquisition)
Indications
Studied for
- Acute Lung Injury
- Anemia, Refractory, with Excess of Blasts
- Anterior Cruciate Ligament Injuries
- Arthritis
- Arthritis, Rheumatoid
- Back Pain
- Bronchitis
- Bronchitis, Chronic
- Colitis
- Colitis, Ulcerative
- Crohn Disease
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Emphysema
- Graft vs Host Disease
- Heart Failure
- Histiocytosis
- Histiocytosis, Langerhans-Cell
- Hodgkin Disease
- Infarction
- Intervertebral Disc Degeneration
- Kidney Diseases
- Leukemia
- Leukemia, Biphenotypic, Acute
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Accelerated Phase
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Low Back Pain
- Lung Diseases
- Lung Diseases, Obstructive
- Lymphoma
- Myelodysplastic Syndromes
- Myocardial Infarction
- Neoplasm, Residual
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Pulmonary Disease, Chronic Obstructive
- Pulmonary Emphysema
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Spinal Stenosis
- Spondylolisthesis
- Syndrome
- Ulcer
Marketed drugs (1)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (50)
- NCT04366830Study directorN/A—
- NCT04456439Lead sponsorN/A—
- NCT04366830Lead sponsorN/A—
- NCT04456439Study directorN/A—
- NCT04543994CollaboratorPhase 1/Phase 2Nov 10, 2020
- NCT04548583CollaboratorPhase 1/Phase 2Nov 4, 2020
- NCT04371393CollaboratorPhase 3Apr 30, 2020
- NCT03096782CollaboratorPhase 2Jun 1, 2017
- NCT02652130Lead sponsorPhase 3Oct 28, 2015
- NCT02652130Study directorPhase 3Oct 28, 2015
- NCT02412735Lead sponsorPhase 3Mar 1, 2015
- NCT02412735Study directorPhase 3Mar 1, 2015
- NCT02336230Lead sponsorPhase 3Jan 1, 2015
- NCT02336230Study directorPhase 3Jan 1, 2015
- NCT02032004Lead sponsorPhase 3Jan 1, 2014
Details
- Founded
- Melbourne, AU Jun 1, 2004
- First NDA
- Dec 18, 2024
- Last known activity
- Dec 18, 2024
Designations held
- Orphan drug